Filariasis

Summary

Filariasis (MONDO:0016075) is a disease (an umbrella term covering 7 Mondo subtypes) and 11 clinical trials. Top therapeutic interventions include doxycycline anhydrous, albendazole, and diethylcarbamazine. A subtype of helminthiasis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: >1 / 1000 (Specific population) [Orphanet-validated]
• Umbrella term: 7 Mondo subtypes
• Clinical trials: 11

Clinical features

Epidemiology

Prevalence records

1 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Point prevalence	>1 / 1000		Specific population	Validated

Identifiers

Disease identifiers

Field	Value
Canonical name	filariasis
Mondo ID	MONDO:0016075
MeSH	D005368
Orphanet	2034
DOID	DOID:1080
ICD-10-CM	B74
ICD-11	1975325075
NCIT	C34611
SNOMED CT	105706003
UMLS	C0016085
MedGen	4706
GARD	0018757
MedDRA	10016674
NORD	1148
Is cancer (heuristic)	no

Disease family

This is a subtype of helminthiasis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › parasitic infectious disease › helminthiasis › filariasis

Related subtypes (21): acanthocephaliasis, heterophyiasis, metagonimiasis, fascioliasis, fasciolopsiasis, monieziasis, clonorchiasis, dicrocoeliasis, echinostomiasis, fascioloidiasis, gnathomiasis, hymenolepiasis, necatoriasis, Nematoda infectious disease, opisthorchiasis, paragonimiasis, trichostrongyloidiasis, schistosomiasis, angiostrongyliasis, intestinal helminthiasis, Cestode infectious disease

Subtypes (7): filarial elephantiasis, mansonelliasis, setariasis, dirofilariasis, dracunculiasis, loiasis, onchocerciasis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

0 approved, 1 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Albendazole	Phase 3 (in late-stage trials)

Clinical trials & evidence

Clinical trials

Clinical trials: 11.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE3	4
Not specified	4
PHASE1	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02927496	PHASE3	COMPLETED	A 24 Month Study, to Compare the Efficacy of Doxycycline vs. Placebo for Improving Filarial Lymphedema in Mali
NCT02929121	PHASE3	COMPLETED	A 24 Month Study to Compare Efficacy of Doxycycline vs Placebo for Improving Filarial Lymphedema in India
NCT02929134	PHASE3	COMPLETED	A 24 Month Study to Compare Efficacy of Doxycycline vs Placebo for Improving Filarial Lymphedema in Sri Lanka
NCT03014167	PHASE3	COMPLETED	Field Studies on the Feasibility of Interrupting the Transmission of Soil-transmitted Helminths (STH)
NCT03383523	PHASE1	COMPLETED	Relative Bioavailability Study of Emodepside IR-tablets and Solution
NCT03383614	PHASE1	COMPLETED	Safety, Tolerability and PK of Multiple-ascending Doses of Emodepside
NCT04920292	PHASE1	COMPLETED	PK, Safety and Tolerability of Single and Multiple Doses of Oxfendazole Tablets
NCT00001230	Not specified	RECRUITING	Host Response to Infection and Treatment in Filarial Diseases
NCT00471666	Not specified	COMPLETED	Medical Implications of Coinfection With Malaria and Filariasis Parasites
NCT01547884	Not specified	COMPLETED	Effect of Filarial Infection on Immune Responses in Latent Tuberculosis
NCT01628497	Not specified	COMPLETED	Exhaled NO Testing in Filariasis

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
DOXYCYCLINE ANHYDROUS	4	9
ALBENDAZOLE	4	1
DIETHYLCARBAMAZINE	4	1
OXFENDAZOLE	2	1